The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Why Sustainability is a Fashion Staple
Will Slaying Inflation Require Recession?
Bear Market Bounce or Stock Market Bottom?
How Inflation, Rates and Recession Are Reshaping the Real Estate Market
Why We’re In a ‘Golden Age’ of Life Sciences Innovation
Food, Fuel, and the Cost-of-Living Crisis
Investing with Permira’s Tara Alhadeff
Asianomics in America: Contributions and Challenges
Investing with Forerunner’s Eurie Kim
Small Business Owners Pivot from Challenges to Opportunities
Investing with Oaktree Capital Management’s Howard Marks
How Companies are Navigating the Energy Transition
Investing with The Carlyle Group’s Sandra Horbach
The Boom in Private Credit
Investing with KKR’s Tara Davies
Goldman Sachs Chairman and CEO David Solomon on the Economy, Investing and Sustainability
Investing with Norges Bank Investment Management’s Nicolai Tangen
Cybersecurity Deals Surge Amid Rising Attacks
Investing with KKR’s Joe Bae
Equity Bear Market: A Paradigm Shift?
Create your
podcast in
minutes
It is Free
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money